Third-line dovitinib in metastatic renal cell carcinoma

被引：13
|
作者：
Schmidinger, Manuela [1 ,2 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Div Clin Oncol, A-1090 Vienna, Austria
[2] Med Univ Vienna, Ctr Comprehens Canc, A-1090 Vienna, Austria
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 03期
关键词：
RESISTANCE;
D O I：
10.1016/S1470-2045(14)70082-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：245 / 246
页数：2
相关论文
共 50 条
  • [1] Third-line Therapy for metastatic Renal cell carcinoma
    Rexer, H.
    [J]. ONKOLOGE, 2011, 17 (12): : 1161 - 1162
  • [2] Third-line Therapy for metastatic Renal Cell Carcinoma
    Rexer, H.
    [J]. UROLOGE, 2011, 50 (10): : 1319 - 1321
  • [3] Third-line treatment in metastatic renal cell carcinoma and bone metastases
    Heng, Daniel Y. C.
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (7-8): : 268 - 268
  • [4] Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
    Roberto, Michela
    Bassanelli, Maria
    Iannicelli, Elsa
    Giacinti, Silvana
    D'Antonio, Chiara
    Aschelter, Anna Maria
    Marchetti, Paolo
    [J]. CASE REPORTS IN ONCOLOGICAL MEDICINE, 2015, 2015
  • [5] Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Wells, J. Connor
    Stukalin, Igor
    Norton, Craig
    Srinivas, Sandy
    Lee, Jae Lyun
    Donskov, Frede
    Bjarnason, Georg A.
    Yamamoto, Haru
    Beuselinck, Benoit
    Rini, Brian I.
    Knox, Jennifer J.
    Agarwal, Neeraj
    Ernst, D. Scott
    Pal, Sumanta K.
    Wood, Lori A.
    Bamias, Aristotelis
    Alva, Ajjai S.
    Kanesvaran, Ravindran
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    [J]. EUROPEAN UROLOGY, 2017, 71 (02) : 204 - 209
  • [6] ACTIVITY OF SUNITINIB AS THIRD-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) (JAPAN)
    Nozawa, M.
    Mochida, Y.
    Nishigaki, K.
    Nagae, S.
    Uemura, H.
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (03) : I11 - I11
  • [7] Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
    Motzer, Robert J.
    Porta, Camillo
    Vogelzang, Nicholas J.
    Sternberg, Cora N.
    Szczylik, Cezary
    Zolnierek, Jakub
    Kollmannsberger, Christian
    Rha, Sun Young
    Bjarnason, Georg A.
    Melichar, Bohuslav
    De Giorgi, Ugo
    Gruenwald, Viktor
    Davis, Ian D.
    Lee, Jae-Lyun
    Esteban, Emilio
    Urbanowitz, Gladys
    Cai, Can
    Squires, Matthew
    Marker, Mahtab
    Shi, Michael M.
    Escudier, Bernard
    [J]. LANCET ONCOLOGY, 2014, 15 (03): : 286 - 296
  • [8] Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy
    Petrioli, Roberto
    Paolelli, Loretta
    Francini, Edoardo
    Marsili, Stefania
    Pascucci, Alessandra
    Sciandivasci, Angela
    de Rubertis, Giovanni
    Barbanti, Gabriele
    Manganelli, Antonio
    Salvestrini, Francesco
    Francini, Guido
    [J]. ANTI-CANCER DRUGS, 2007, 18 (07) : 817 - 820
  • [9] Outcome of third-line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma
    Fujita, Tetsuo
    Hirayama, Takahiro
    Nishi, Morihiro
    Matsumoto, Kazumasa
    Yoshida, Kazunari
    Iwamura, Masatsugu
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (05) : 505 - 510
  • [10] Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
    Di Lorenzo, Giuseppe
    Buonerba, Carlo
    Federico, Piera
    Rescigno, Pasquale
    Milella, Michele
    Ortega, Cinzia
    Aieta, Michele
    D'Aniello, Carmine
    Longo, Nicola
    Felici, Alessandra
    Ruggeri, Enzo Maria
    Palmieri, Giovannella
    Imbimbo, Ciro
    Aglietta, Massimo
    De Placido, Sabino
    Mirone, Vincenzo
    [J]. EUROPEAN UROLOGY, 2010, 58 (06) : 906 - 911
12345